All posts by Epic

With Breakthrough Medical devices, ODYY could be the Next Big FDA Decision play to go PARABOLIC!

odyy logo

Last Price: .75  |  Website  |  SEC Filings  |  Latest News

We’ve all heard those “Rags to Riches” stories when it comes to FDA Decision Stocks….

Little-known Sarepta Therapeutics (SRPT) was trading at $3 in 2012 before it’s muscular dystrophy drug, Eteplirsen, received FDA Approval and never looked back.  Today the stock trades near all-time highs of $172 – delivering a mind-blowing 2,300%+ GAIN!

Even more recently, Quidel Corp. skyrocketed 312% from around $60. last year to All-Time Highs of $2.27 today on FDA Approval for their COVID-19 antigen test!

These are just 2 examples of the kind of LIFE-CHANGING GAINS early investors can see from an FDA Approval decision.

And that’s why we’re so excited about this week’s New Alert – especially since it’s trading at a mere .75!!


Odyssey Group International (OTCQB: ODYY) is a technology and asset acquisition company with a focus in the area of life-saving medical solutions.

The company operates in the Medical technology industry which represents $430 billion dollars of the overall Healthcare Industry.  And with ODYY’s ground-breaking projects, this company looks like they will be a key piece of the sector for a long time to come!

ODYY is quickly gaining notoriety on the strength of it’s two potential FDA Approval medical devices: CardioMap® and Save-A-Life Choking Rescue Device.

These revolutionary devices are absolutely one-of-a-kind!! 

CardioMap®, for example, provides early, non-invasive testing for heart disease – the leading cause of death among Americans today with cardiac devices representing a $28 BIL market!

Save-a-Life is a patented, safe, and easy to use vacuum device for removing a lodged mass or bolus from the throat of a choking victim.

Yes…ODYY is *quite literally* out there to SAVE LIVES!!!

Yet, ODYY is now trading *well off* very recent highs of 4.95 from just over a month ago….

Now trading in a consolidated channel right at long-term support levels, could an EPIC BOUNCE be in the cards?

In fact, ODYY is literally trading back at the same exact price of .75 when it rallied 560% to highs of 4.95 in April!!

So with our MACD Indicator suggesting Bullish sentiment and Divergence + our RSI Indicator now completely OVERSOLD…..could History repeat itself this week??

Let’s dig in…


The United States remains the largest medical device market in the world at over $150 billion and the market is expected to grow to an impressive $400+ billion.

When you compare the space to other industries like automotive, defense, and telecommunications, the medical device industry invests a higher percentage of yearly revenues into product innovation.

This is a competitive arena where companies are constantly trying to improve on existing products and technologies.

The global medical devices market should expand at a CAGR of 4.5% over the next four years, reaching a total of $409.5 billion by the year 2023, says a new report by Lucintel.

Many baby boomers already represent a major market with many more heading into retirement. The baby boomer population is now estimated at about 73 million!

The need for life changing and life saving medical devices is dire and ODYY is looking to capitalize with several products that may eventually become household names!


ODYY’s footprint in the healthcare sector can be summed into 3 different projects…

The company’s initial product technology is the CardioMap® heart monitoring and screening device.

ODYY also acquired the patented Save-a-Life Choking Rescue Device – a personal anti-choking device to save lives.

And last but not least, ODYY struck a partnership with Prevacus Inc., a BioPharma company that has been developing a nasal spray to treat concussions and other rare neurological disorders.

ODYY’s CardioMap® heart monitoring and screening device, provides early, non-invasive testing of heart disease.

CardioMap was originally designed for doctor’s offices and hospitals, but can be easily transformed for personal use or alternative setting (gyms, spa’s, home, ambulatory care and/or clinics). The current technology is much more sensitive and accurate than traditional EKG technology.

With its highly portable design and web-based analysis, it can both penetrate the existing $28B cardiac device market and also expand the market vertical by opening up the possibilities for remote and home screening.


CardioMap depicts disease or stress levels, along with current heart conditions as a 3D image supplementing the line drawing electrocardiogram (ECG), but with device sensitivity that surpasses standard ECG analyzers by 7 to 50 times.

It is highly portable and provides a rapid analysis in less than 60 seconds. The device is connected through the internet to the central server that converts the electric conductivity of the cardiac tissue into a three-dimensional, color-coded and easy to interpret visual portrait.

If it becomes FDA approved, ODYY’s CardioMap will be the first and only device capable of mass screening for early detection!

All other methods presently used, including ECG, Stress Tests, EHO, etc. either define patients as ‘healthy’ (no pathology, no changes) or ‘sick’ (there is a pathology and/or organic changes).

The CardioMap could also be the only device that has the ability to show the ‘grey’ areas where deterioration has begun but not lead to pathology yet. This is a phenomenal incentive for doctors to use the CardioMap device.

With its asset acquisition of Save-a-Life, ODYY is now organized to introduce to the medical device industry a revolutionary, easy-to-use choking rescue device.

save a life

Save-a-Life is a patented, safe, and easy to use vacuum device for removing a lodged mass or bolus from the throat of a choking victim.

The device includes a pump for creating a vacuum chamber which is connected seamlessly with a replaceable/disposable mouthpiece. In an emergency the CRD may be easily inserted into the victim’s mouth which depresses the tongue providing a clear, trauma-free application.


Some of the many advantages of this device include:

► It’s easy to use
► Has a smart patented design
► Can be used on anyone (of any age)
► The product can be self-administrable

KEEP IN MIND: There are approximately 5,000 choking deaths annually in the US. 95% of these result from in-home incidents. 56% of these victims are over 74 years in age.

Choking is the 4th leading cause of death in children, and airway obstruction is the leading cause of unintentional injury-related deaths under the age of 1 in the United States. Current choking rescue devices do not address these needs.

ODYY believes its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally – literally “SAVING LIVES”!

The company and their design partner has made progress in its development effort with the ultimate goal of filing a submission to the FDA for the life-saving choking rescue device.

So far they have accomplished phase one design tasks and built a working proof of principle model for testing repeatable performance and efficacy in a life-like anatomical model. This mechanical device has demonstrated its ability to extract a variety of lodged food samples from confined areas in the airway passage that typically cause asphyxiation.

Last June, ODYY struck a partnership deal with Prevacus Inc., a company that has been developing a nasal spray to treat concussions.

Prevacus, Inc. is a BioPharmaceutical company which is developing drug candidates that have the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders.

The Company’s first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.

We’ve seen concussions destroy the lives of wealthy and powerful athletes from wrestling to football.

Yet there are currently NO DRUG AVAILABLE for concussion treatment.

Prevacus’ founder, Jacob VanLandingham, is a Ph.D. who worked in the Department of Biomedical Sciences for the FSU College of Medicine. He has spent many years in the laboratory analyzing the positive effects neuro-steroids have on edema– swelling of the brain.

The Odyssey-Prevacus partnership could quite possibly facilitate the release of the FIRST EVER concussion treatment drug.  This would be an IMMENSE feat in an untouched market!!

The nasal spray is currently in the early stages of testing.

ODYY and Prevacus are now preparing the final nano-formulation for nasal application to initiate its first human trials for treating concussion.

If you’ve read this far, you’ve got to be convinced that what ODYY has in the pipeline is downright REVOLUTIONARY.

This is not a company that shies away from doing the unthinkable and going after diseases that most other Pharmas would steer clear of.

Heart Disease?  The #1 annual killer of Americans. ODYY is on it.
Concussions?  Currently NO Drugs on the market.  ODYY is on it.
Choking? Good luck there. But ODYY is on it.

So needless to say, we’ll be watching closely to see how all these devices progress through the FDA pipeline!

In the meantime, ODYY is trading at Bottomed Support levels at the VERY SAME PRICE of .75 that it rallied 560% from in April!!

So will history repeat itself today?

Make sure you put ODYY on your screen RIGHT NOW and Follow on Twitter for Updates + Play-by-Play!



We encourage all to read the SEC INVESTOR ALERT before reading our Newsletter.

COMPENSATION: has been compensated seventy thousand dollars cash via bank wire by a third party, Electrik Dojo LLC for a two day Odyssey Group International Inc. marketing services contract. does not own any shares of ODYY. does not investigate the background of any third party. The third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.


Sign up for Text Message Alerts

The FASTEST WAY to receive our Alerts!

Fill out the form to receive our text alerts or simply Text the word: EPIC to the number: 71441.

Mobile Number:

Standard Message and Data Rates Apply.

At anytime you can reply to any text with the word ‘HELP‘ to
get more information or ‘STOP‘ to cancel your account. Terms of Service | Privacy Policy

Mobile Number:

Standard Message and Data Rates Apply.

At anytime you can reply to any text with the word ‘HELP‘ to
get more information or ‘STOP‘ to cancel your account. Terms of Service | Privacy Policy


IPRU (Innovative Product Opportunities, Inc.) is our New Epic Pick!Last Trade: .0017  |  SEC Filings  |  Latest News

Begin your research at

Today we intend to close the month of March in a big way with what may be the most innovative Tech Sub-Pennies on the OTC markets today!

Touchscreen technology is no longer a “new thing”.  It’s everywhere from our smartphones and tablets to our laptop computers.  However, today’s alert is utilizing this technology in not only a unique and interactive way – but literally – in a BIG WAY. Introducing…IPRU!


IPRU has taken touch technology to the next level by successfully engaging consumers using much larger mediums such as floor screens, table tops and window displays.  The company currently claims resellers in 21 countries and names Disney, Sony, Guess and Mazda among some of their clients!

Sounds amazing right?  But equally amazing is IPRU’s incredibly BULLISH chart….

IPRU’s most recent Bullish run is nothing short of astonishing.

From Triple-Zero levels of .0002 in January to today’s price of .0017 – IPRU has certainly come a long way!

But could IPRU be ready to rise to the next level?

IPRU has now developed an impressive Bullish Trend which has held for over 2 months.

However, like kryponite, IPRU has failed to breach  .0017 after testing it over 12 times in the last month.

With all indicators now Bullish, we’ll be watching for a potential break of this key level to confirm a continuation to this trend.

On our side is who currently gives IPRU it’s top rating of STRONG BUY!  In addition, StockTA currently gives it a BULLISH overall rating!

IPRU (Innovative Product Opportunities, Inc.) is a research and product development firm specializing in interactive media products.  At the core is the company’s proprietary technology which turns ordinary surfaces into exciting self-motivated digital experiences.

IPRU brings static environments to life by enhancing existing infrastructure with interactive effects. The company can convert walls, floors, windows, and tables into a literal digital playground!

This allows IPRU to provide clients with a fresh new approach to delivering their messages and enhancing their brand through interactive multi-touch and even multi-user recognition – the more participants, the merrier!

But instead of trying to explain it, you can see it with your own eyes!  Click Play on the video below:

Did you see that?  IPRU has created video lighting for floors, walls, windows, displays, and more to react and animate to the user’s movements!  INCREDIBLE!

IPRO has absolutely taken touch to the next level.

Their core software, the heart of Imagin8, is a powerful and easy to use proprietary platform that allows it to simply track hand and body movement.

Think about all the concerts, nightclubs, broadway plays, retail stores, and  more that could use this technology!  The possibilities are ENDLESS!

In fact, I have personally seen this technology used at Muse concerts.  IPRU has already implemented it’s technology in a top Toronto nightclub that now has an interactive bartop and has tested it’s technology with a multi-platinum Grammy-award winning Artist!

IPRU is certainly not a company to simply rest on it’s laurels.
Earlier this month, IPRU announced a partnership with Lusens Inc. – a company specializing in many of the same technologies.  Check out Lusens’ amazing products, installations, and technologies HERE

Already this partnership appears to be paying off as the companies worked closely to deliver an Interactive Donor Recognition Wall to the Toronto Humane Society!

Amazing Technology, Growth, new partnerships, a Sub-Penny Pricetag, and a Bullish Chart….What’s not to love about IPRU?!

Make sure you put it on your screen RIGHT NOW and Follow on Twitter for all the Updates + Play-by-Play!

Good Trading,


GO VIP for a Limted Time Only!  Read More…

Please read our Full Disclaimer:

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.  The paying party may own shares and may liquidate them during the promotional period.

PLEASE NOTE WELL: and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. EPICSTOCKPICKS.COM WILL NEVER ACCEPT FREE OR RESTRICTED TRADING SHARES IN ANY COMPANIES MENTIONED at EPICSTOCKPICKS.COM &/OR ANY OF OUR SOCIAL NETWORKING AND EMAIL ADVERTISING PLATFORMS.

You are reading this newsletter because you have subscribed via our Opt-In Signup form on our Website. If you have been subscribed by mistake, you may unsubscribe here.

Our website and newsletter are for entertainment purposes only. This newsletter is NOT a source of unbiased information.  Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Gains mentioned in our newsletter and on our website may be based on End of Day or intraday data. The disclaimer is to be read and fully understood before using our site, or joining our email list. Full disclaimer can be read at

We encourage all to read the SEC’s INVESTOR ALERT before reading our Newsletter.

Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by or an offer or solicitation to buy or sell any security.

COMPENSATION: has been compensated fifty-nine thousand dollars cash via bank wire by a third party, Cream Consulting Group, Inc. for a one day, Innovative Product Opportunities, Inc. advertising services contract. has been previously compensated twenty thousand dollars cash via bank wire by a third party, Microcap Innovations, LLC for a one day, Innovative Product Opportunities, Inc. advertising services contract which has expired. does not own any shares of IPRU. does not investigate the background of any third party. The third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. may purchase shares on the open market of any mentioned company following the dissemination of this email. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is collected from public sources only such as the profiled company’s website, news releases, and corporate filings, but has not been verified in any way to ensure the publicly available information is correct. makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further, has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news press releases, changes in corporate structure, or changes in share structure.

None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. is compliant with the Can Spam Act of 2003. does not offer such advice or analysis, and further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.  Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.

In preparing this publication, has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. is not responsible for any claims made by the companies advertised herein, nor is responsible for any other promotional firm, its program or its structure.